Michael B Streiff
Overview
Explore the profile of Michael B Streiff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
213
Citations
3692
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hager D, Zhu Y, Sohn I, Stubblefield W, Streiff M, Gaglani M, et al.
J Infect Dis
. 2024 Oct;
231(2):378-385.
PMID: 39405261
Background: Coronavirus disease 2019 (COVID-19) is a strong risk factor for venous thromboembolism (VTE). Few studies have evaluated the effectiveness of COVID-19 vaccination in preventing hospitalization for COVID-19 with VTE....
2.
Streiff M, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, et al.
J Natl Compr Canc Netw
. 2024 Sep;
22(7):483-506.
PMID: 39236759
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and...
3.
Fera T, Burnett A, Grandoni J, Moore M, Nussbaum B, Pollack Jr C, et al.
J Pharm Pract
. 2024 Jul;
38(1):7-12.
PMID: 39030931
Medication-use evaluations are meant to ensure that medication-use processes are consistent with prevailing standards of care, assure optimal use of therapy, and reduce the risk of medication-related problems. Reversal agents...
4.
Hoyer E, Bhave A, Xue W, Haut E, Lau B, Kraus P, et al.
Am J Med
. 2024 Apr;
137(8):776-781.
PMID: 38649003
Background: Venous thromboembolism risk increases in hospitals due to reduced patient mobility. However, initial mobility evaluations for thromboembolism risk are often subjective and lack standardization, potentially leading to inaccurate risk...
5.
LeMaistre F, Chiang E, Streiff M, Yui J
Blood Coagul Fibrinolysis
. 2024 Apr;
35(4):206-208.
PMID: 38625829
Type 3 von Willebrand disease (T3VWD) is a rare inherited bleeding disorder caused by the absence of von Willebrand factor (VWF). The traditional treatment for T3VWD has been VWF concentrates,...
6.
Pecker L, Burke A, Streiff M, Lanzkron S, Naik R
Res Pract Thromb Haemost
. 2023 Sep;
7(6):102183.
PMID: 37711908
No abstract available.
7.
Lau B, Shaffer D, Kraus P, Owodunni O, Kia M, Chiochetti S, et al.
Qual Manag Health Care
. 2023 Aug;
32(4):281-282.
PMID: 37651594
No abstract available.
8.
Chaturvedi S, Yu J, Brown J, Wei A, Selvakumar S, Gerber G, et al.
Blood
. 2023 May;
142(4):325-335.
PMID: 37216688
Immune thrombotic thrombocytopenic purpura (iTTP) survivors have increased risk of cardiovascular disease, including strokes, and report persistent cognitive difficulties during remission. We conducted this prospective study involving iTTP survivors during...
9.
Zuckerman S, Berven S, Streiff M, Kerolus M, Buchanan I, Ha A, et al.
Spine (Phila Pa 1976)
. 2023 Feb;
48(5):301-309.
PMID: 36730667
Study Design: Delphi method. Objective: To gain consensus on the following questions: (1) When should anticoagulation/antiplatelet (AC/AP) medication be stopped before elective spine surgery?; (2) When should AC/AP medication be...
10.
Ardeshirrouhanifard S, Ellenbogen M, Segal J, Streiff M, Deitelzweig S, Brotman D
Thromb Res
. 2022 Dec;
221:45-50.
PMID: 36470069
Introduction: Evidence suggests that an apixaban-based strategy to treat acute venous thromboembolism (VTE) in patients with End-Stage Kidney Disease (ESKD) may be safer than a warfarin-based strategy. Apixaban has an...